Finerenone for Premature Ovarian Insufficiency (POI)
Key facts
- Who runs it
- The University of Hong Kong-Shenzhen Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 46 people, planned
- Started
- 15 Sept 2026
- Expected to end
- Sept 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Finerenone
- Placebo
- Record updated
- 11 September 2026
Who can take part
- Age
- 18 years to 39 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age of women <40 years
- Diagnosis of POI according to ESHRE 2024 guidelines, defined as:
- Oligomenorrhea or amenorrhea for at least 4 months; and
- Elevated FSH levels (≥25 mIU/mL) on a single measurement
Who cannot take part
- Known hypersensitivity to Finerenone or any of its excipients
- Severe uncontrolled systemic diseases (cardiovascular, hepatic, renal, or endocrine disorders) that may interfere with study participation
- Active malignancy or history of hormone-dependent cancer
- Known chromosomal abnormalities or clinically significant genetic syndromes associated with POI
- Currently participating in another interventional trial
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Premature ovarian insufficiency
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is testing whether finerenone, a medicine currently used to protect the kidneys and heart, can help women with premature ovarian insufficiency (POI) grow ovarian follicles and produce eggs that can be collected for in vitro fertilization (IVF). Women with POI often have very few or no active egg-containing follicles, making it hard for them to conceive. About 46 women with POI will be randomly assigned, without either the participants or their doctors knowing the assignment, to take either finerenone or a matching placebo twice weekly for 24 weeks. Participants will be monitored regularly with ultrasound and blood tests. If follicle growth is observed, participants may undergo ovarian stimulation so that eggs or embryos can be collected and frozen. The main goal is to see whether more women in the finerenone group have eggs successfully retrieved during an IVF cycle, compared with the placebo group. The study will also look at other measures of ovarian reserve, egg and embryo quality, and pregnancy outcomes among participants who go on to embryo transfer.
The 2 groups in the trial
- FinerenoneTreatment being tested
Participants received oral finerenone 20 mg twice weekly for 24 weeks during the double-blind treatment phase.
- PlaceboPlacebo, for comparison
Participants received matching placebo tablets, oral, twice weekly for 24 weeks during the double-blind treatment phase.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Trial of Finerenone in Women With Premature Ovarian Insufficiency
- Criteria questions
- Built from NCT07815509, who can take part
- Record updated
- 11 September 2026